CAR T Cells with Dual Targeting of CD19 and CD22 in Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia: A Phase I Trial

Researchers conducted a Phase I trial in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 chimeric antigen receptors (CARs).